Ashiq Masood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3280410/publications.pdf

Version: 2024-02-01

1			430843	552766	
	30	1,316	18	26	
	papers	citations	h-index	g-index	
	32	32	32	2456	
	32	32	32	2 130	
	all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology, 2022, 23, 113 .	8.8	48
2	Correction: Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology, 2022, 23, .	8.8	3
3	Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress) Journal of Clinical Oncology, 2021, 39, TPS451-TPS451.	1.6	O
4	The Prognostic Role of the Neutrophil to Lymphocyte Ratio at Recurrence in Esophageal Squamous Cell Carcinoma: Challenges and Future Directions. Annals of Surgical Oncology, 2021, 28, 2939-2940.	1.5	2
5	Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition. Npj Genomic Medicine, $2021, 6, 23$.	3.8	6
6	A pan-cancer organoid platform for precision medicine. Cell Reports, 2021, 36, 109429.	6.4	45
7	Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. Journal of Clinical Oncology, 2021, 39, 3747-3758.	1.6	38
8	Current and emerging therapies for advanced biliary tract cancers. The Lancet Gastroenterology and Hepatology, 2021, 6, 956-969.	8.1	81
9	Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 1314-1315.	1.5	O
10	Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. International Journal of Molecular Sciences, 2020, 21, 7651.	4.1	36
11	Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. Cancers, 2019, 11, 1164.	3.7	12
12	Emergence of <i>ERBB2</i> Mutation as a Biomarker and an Actionable Target in Solid Cancers. Oncologist, 2019, 24, e1303-e1314.	3.7	64
13	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Seminars in Oncology, 2019, 46, 271-283.	2.2	61
14	Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. Cancers, 2019, 11, 1399.	3.7	27
15	Pembrolizumab in newly diagnosed EBVâ€'negative extranodal natural killer/Tâ€'cell lymphoma: A case report. Molecular and Clinical Oncology, 2019, 10, 397-400.	1.0	13
16	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	9.6	51
17	Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers. Molecular Cancer Therapeutics, 2018, 17, 1123-1132.	4.1	19
18	The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 707-714.	1,1	41

#	Article	IF	CITATIONS
19	The evolving genomic landscape in urothelial cancer. Current Opinion in Oncology, 2018, 30, 197-202.	2.4	7
20	Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	1.6	223
21	Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Molecular Cancer, 2018, 17, 177.	19.2	80
22	P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET. Journal of Thoracic Oncology, 2017, 12, S1080-S1081.	1.1	4
23	P1.07-035 Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S717-S718.	1.1	4
24	A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer. Genome Research, 2016, 26, 745-755.	5. 5	233
25	Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC. Journal of Thoracic Oncology, 2016, 11, 1729-1735.	1.1	74
26	Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. Journal of Oncology Pharmacy Practice, 2013, 19, 18-23.	0.9	12
27	Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents. Cancers, 2011, 3, 428-445.	3.7	48
28	Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. Cancers, 2011, 3, 1527-1549.	3.7	31
29	Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells. Blood, 2011, 118, 4390-4390.	1.4	1
30	Primary Non-Hodgkin Lymphoma of Liver. Current Oncology, 2009, 16, 74-77.	2.2	49